Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
BASKING RIDGE, N.J., April 10, 2017 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that the Company’s 2017 annual stockholder meeting will be held on Tuesday, May 16, 2017 at 11:00 a.m., Eastern Daylight Savings Time, at Hotel Indigo Basking Ridge, 80 Allen Road, Basking Ridge, NJ 07920.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The Company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information on Caladrius please visit www.caladrius.com.
Contacts: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: [email protected] Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: [email protected]
